MEDI4736

Mayo Clinic Investigator Discusses Remaining Questions on AstraZeneca’s PACIFIC Clinical Trial in Lung Cancer

Aug 28, 2019 | Cancer, Human Monoclonal Antibody, Lung Cancer, MEDI4736, Non-Small Cell Lung Cancer, Oncology

Sponsored by AstraZeneca, the PACIFC study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI14736 (durvalumab) as Sequential Therapy in Patients with Locally advanced, unresectable non-small cell lung cancer...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Mayo Clinic Investigator Discusses Remaining Questions on AstraZeneca’s PACIFIC Clinical Trial in Lung Cancer

Pin It on Pinterest